Increased urinary excretion of the prostaglandin D2 metabolite 9α, 11β-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction

Journal of Allergy and Clinical Immunology

Volumn 98, Issue 2, 1996, Pages 421-432

  O'Sullivan, Siobhán ^a,b   Dahlén, Barbro ^b   Dahlén, Sven Erik ^a,b   Kumlin, Maria ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

11 prostaglandin F2; Aspirin induced asthma; Enzyme immunoassay; Leukotrienes; Mast cell; Prostaglandin D2; Urinary 9

Indexed keywords

11 EPIPROSTAGLANDIN F2 ALPHA; ACETYLSALICYLIC ACID; ALLERGEN; HISTAMINE; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LYSINE ACETYLSALICYLATE; PROSTAGLANDIN D2 DERIVATIVE; VERLUKAST;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; BRONCHOSPASM; CELL STIMULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAST CELL; PRIORITY JOURNAL; PROVOCATION TEST; URINARY EXCRETION;

ADULT; AIRWAY OBSTRUCTION; ALLERGENS; ASPIRIN; ASTHMA; BRONCHIAL PROVOCATION TESTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DINOPROST; DOUBLE-BLIND METHOD; HISTAMINE; HUMANS; IMMUNOENZYME TECHNIQUES; LYSINE; MAST CELLS; MIDDLE AGED; PROSTAGLANDIN D2;

EID: 0029792693     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(96)70167-7     Document Type: Article

References (50)

1. Samter M, Beers RF. Intolerance to aspirin. Clinical studies and considerations of its pathogenesis. Ann Intern Med 1968;68:975-83.
2. Stevenson DD. Diagnosis, prevention and treatment of adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol 1984;74:6617-22.
3. Szeczklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in ASA-sensitive patients. Br Med J 1975;1:67-9.
4. Samuelsson B, Dahlén S-E, Lindgren JÅ, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structure, biosynthesis, and biological effects. Science 1987;237:1171-6.
5. 4 by human eosinophils. J Immunol 1987;138:532-8.
6. MacGlashan DWJ, Schleimer RP, Peters SP, et al. Generation of leukotrienes by purified human lung mast cells. J Clin Invest 1982;70:747-51.
7. 4, and histamine in asthmatics. Am Rev Respir Dis 1992;146:96-103.
8. 4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991;143:1025-9.
9. Picado C, Ramis I, Rosellò J, et al. Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am Rev Respir Dis 1992;145:65-9.
10. Sladek K, Dworski R, Soja J, et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 1994;149:940-6.
11. Christie P, Smith C, Lee T. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991;144:957-8.
12. Dahlén B, Kumlin M, Margolskee DJ, et al. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 1993;6:1018-26.
13. Yamamoto H, Nagata M, Kuramitsu K, et al. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 1994;150:254-7.
14. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993;148:1447-51.
15. Dahlén B, Margolskee DJ, Zetterström O, and Dahlén S-E. Effect of the leukotriene-antagonist MK-0679 on baseline pulmonary function in aspirin-sensitive asthmatics. Thorax 1993;48:1205-10.
16. Dahlén S-E, Nizankowska E, Dahlén B, et al. The Swedish-Polish treatment study with the 5-lipoxygenase inhibitor zileuton in aspirin-intolerant asthmatics [abstract]. Am J Respir Crit Care Med 1995;151:A376.
17. Dahlén B, Zetterström O, Dahlén S-E. Specific problems: asthma induced by aspirin and other non-steroidal antiinflammatory drugs. In: O'Byrne P, Thomson NC, editors. Manual of asthma management. London: Saunders, 1995:590-606.
18. Friedlaender S, Feinberg S. Aspirin allergy: its relationship to chronic intractable asthma. Ann Intern Med 1947;26:734-40.
19. 4. Proc Natl Acad Sci USA 1983;80:7626-30.
20. 2 generation after activation of rat and human mast cells with anti-IgE. J Immunol 1982;129:1627-31.
21. 2 in patients with systemic mastocytosis. N Engl J Med 1980;180:1400-4.
22. 2 in a normal human male volunteer. J Biol Chem 1985;260:13172-80.
23. Dahlén B and Zetterström O. Comparison of bronchial and per oral provocation with aspirin in aspirin-sensitive asthmatics. Eur Respir J 1990;3:527-34.
24. 4 in humans. Effects of indomethacin. Am Rev Respir Dis 1990;141:1441-5.
25. Granström E, Kumlin M. Metabolism of prostaglandins and lipoxygenase products: relevance for eicosanoid assay. In: Benedetto C, McDonald RG, Nigam S, Slater TF, editors. Prostaglandins and related substances: a practical approach. Oxford: IRL Press, 1987:5-27.
26. 4 in humans. Clin Exp Allergy 1995;25:467-79.
27. Dahlén B, Zetterström O, Björck T, and Dahlén S-E. The leukotriene-antagonist ICI-204, 219 inhibits the early air-way reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J 1994;7:324-31.
28. Pradelles P, Grassi J, Maclouf J. Enzyme immunoassays of eicosanoids using acetylcholinesterase. Methods Enzymol 1990;187:24-34.
29. 2 into human airways during acute antigen challenge. N Engl J Med 1986;315:800-4.
30. 4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990;142:112-9.
31. Dworski R, Fitzgerald GA, Oates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994;149:953-9.
32. Roberts LJI, Oates JA. Evidence against a role of mast cell cyclooxygenase inhibition in aspirin hypersensitivity reactions [abstract]. Clin Res 1983;31:165A.
33. Butterfield JH, Klee GG, Yocum MW. Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization. Mayo Clin Proc 1995;70:481-7.
34. 2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 1989;38:263-74.
35. 2): a unique biologically active prostaglandin produced enzymatically in vivo in humans. Proc Natl Acad Sci USA 1985;82:6030-4.
36. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ II. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990;87:9383-7.
37. Morrow JD, Harria TM, Roberts LJ II. Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramification for measurements of eicosanoids. Anal Biochem 1990;184:1-10.
38. Schulman ES, MacGlashan DWJ, Schleimer RP, et al. Purified human basophils and mast cells: current concepts of mediator release. Eur J Respir Dis 1983;(suppl 128):53-61.
39. 4 excretion in exercise-induced asthma. J Appl Physiol 1992;73:743-8.
40. 4 in guinea-pig lung in vitro. Br J Pharmacol 1982;77:267-75.
41. 4 in the guinea pig depends upon the route of administration. Acta Physiol Scand 1983;53:589-95.
42. Schulman ES, Adkinson NFJ, Newball HH. Cyclooxygenase metabolites in human lung anaphylaxis: airway vs. parenchyma. J Appl Physiol 1982;53:589-95.
43. Fisher AR, Rosenberg MA, Lilly CM, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994;94:1046-56.
44. Ferreri NR, Howland WC, Stenvenson DD, Spiegelberg HL. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis 1988;137:847-54.
45. Schwartz LB, Austen KF. Structure and function of the chemical mediators of mast cells. Prog Allergy 1984;34:271-321.
46. Bosso J, Schwartz L, Stevenson D. Tryptase and histamine release during aspirin-induced respiratory reactions. J Allergy Clin Immunol 1991;88:830-7.
47. Sladek K, Szczeklik A. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur Respir J 1993;6:391-9.
48. Hamrin B. Release of histamine in urticaria pigmentosa. Lancet 1957;1:867-8.
49. Schumberger H, Lobbecke E, Kallos P. Acetylsalicylic acid tolerance. Acta Med Scand 1974;196:451-8.
50. Weltman J, Szaro R, Settipane G. An analysis of the role of IgE in tolerance to aspirin and tartrazine. Allergy 1978;34:273-81.